Roles
- Associate Professor of Clinical Pediatrics
- Pediatric Hematology, Oncology, Bone Marrow Transplant and Cellular Therapy
-
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Finding New Solutions for Pediatric Sarcoma Patients
Sylvester Researchers Receive Grant from Hyundai Hope On Wheels
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 5 clinical trials.
-
For the treatment study, the goal is to determine which treatment option is best to start with for patients with SAA, between a matched unrelated donor bone marrow transplant or immune suppressive therapy, when a matched related donor is not available. We’re doing this study to see whether immune suppressive therapy or bone marrow transplant is best to start with in patients with SAA who have a potential unrelated donor available.
- Principal Investigator: Warren Alperstein
- Study Phase: Phase III
- Enrollment Status: Closed
-
To improve the survival of children with certain forms of blood cancer who need a hematopoietic stem cell transplantation by adding specially selected immune cells from the donor to the conventional stem cell product
- Principal Investigator: Warren Alperstein
- Study Phase: Phase I/II
- Enrollment Status: Not Accepting
-
To determine overall response rate (ORR) for children and young adults with relapsed or refractory BRAFV600E positive (cohort 1) and BRAFV600E negative (cohort 2) Langerhans cell histiocytosis (LCH) treated with tovorafenib (DAY101) after 2 cycles and must be maintained 4 weeks later.
- Principal Investigator: Warren Alperstein
- Study Phase: Phase II
- Enrollment Status: Open
-
To compare the progression-free survival (PFS) of a standard chemotherapy approach versus an immunotherapy (IO) approach (brentuximab vedotin and nivolumab) in patients with newly diagnosed early stage classic Hodgkin lymphoma (cHL) who have a rapid early response (RER) as determined by position emission tomography post cycle 2 (PET2) after 2 cycles of doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) chemotherapy.
- Principal Investigator: Warren Alperstein
- Study Phase: Phase III
- Enrollment Status: Open
-
An Open-label, Single-arm, Multicohort, Phase 2 Study to Assess the Efficacy and Safety of Tabelecleucel in Subjects With Epstein-Barr Virus-associated Diseases
- Principal Investigator: Warren Alperstein
- Study Phase: Phase 2
- Enrollment Status: Not Accepting